The novel drugs work by mimicking the gut hormone GLP-1, which lowers blood sugar and limits the appetite. Treatments such as ...

The bloom may be off the rose for obesity drugs as reports of side effects for high doses of GLP-1 drugs. GLP-1s were ...

However, the analysts said: “Given our own forecast that CPI inflation will rise back to 2.9pc by January next year (perhaps ...

Weight loss drugs like Novo Nordisk’s semaglutide and Eli Lilly ... although semaglutide is also available as a daily oral pill. LLY and NVO have other weight loss drugs in the pipeline.

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

Shares were down 4.3% at 1330 GMT, the lowest since August 8, after the company announced headline results from its trial of ...

Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people ...

There is a new chapter in Big Pharma’s billion-dollar war on obesity, as Novo Nordisk and Eli Lilly battle it out over the latest blockbuster drugs. Ozempic maker Novo Nordisk’s highly ...

Novo Nordisk (NVO) (OTCPK:NONOF) ADRs traded higher in the premarket on Wednesday after the Danish drugmaker released full results from an early-stage trial for its experimental weight-loss pill ...